• LAST PRICE
    8.6000
  • TODAY'S CHANGE (%)
    Trending Down-0.0900 (-1.0357%)
  • Bid / Lots
    7.5300/ 2
  • Ask / Lots
    8.9900/ 3
  • Open / Previous Close
    8.5100 / 8.6900
  • Day Range
    Low 8.2679
    High 8.7400
  • 52 Week Range
    Low 7.3000
    High 10.9600
  • Volume
    1,930
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Thursday's close: 8.69
TimeVolumeICCC
09:32 ET1578.51
01:15 ET1008.32
01:30 ET1008.5
02:44 ET1008.74
02:58 ET2008.355
03:12 ET1288.2679
03:59 ET1518.6
Data delayed at least 15 minutes.
No documents available
0 New Today
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesICCC
ImmuCell Corp
66.6M
61.0x
---
United StatesLPCN
Lipocine Inc
70.8M
-93.6x
---
United StatesHARP
Harpoon Therapeutics Inc
62.2M
-0.8x
---
United StatesSLDB
Solid Biosciences Inc
65.0M
-0.8x
---
United StatesCDAK
Codiak BioSciences, Inc.
58.0M
-1.6x
---
United StatesMDWD
Mediwound Ltd
59.3M
-3.5x
---
As of 2022-07-04

Company Information

ImmuCell Corporation is an animal health company. The Company is engaged in development, acquisition, manufacture and sale of products that improve the health and productivity of dairy and beef cattle. It manufactures and markets the First Defense product line for the prevention of scours in newborn dairy and beef calves. It expanded this line into five different products with formulations targeting E. coli and coronavirus pathogens, as well as E. coli, coronavirus and rotavirus pathogens. Its Tri-Shield First Defense product line extension is calf-level, passive antibody product providing immediate immunity against E. coli, coronavirus and rotavirus. These product line provides Immediate Immunity to newborn calves. The Company is engaged in development of Re-Tain, a Nisin treatment for subclinical mastitis in lactating dairy cows. Its products reduce the use of traditional antibiotics in food producing animals.

Contact Information

Headquarters
56 Evergreen DrPORTLAND, ME, United States 04103-1066
Phone
207-878-2770
Fax
302-655-5049

Executives

Chairman of the Board
David Tomsche
President, Chief Executive Officer, Treasurer, Secretary, Director
Michael Brigham
Vice President - Sales and Marketing, Director
Bobbi Brockmann
Vice President - Manufacturing Operations
Elizabeth Williams
Independent Director
Gloria Basse

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$66.6M
Revenue (TTM)
$21.1M
Shares Outstanding
7.7M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
0.61
EPS
$0.14
Book Value
$4.21
P/E Ratio
61.0x
Price/Sales (TTM)
3.2
Price/Cash Flow (TTM)
18.7x
Operating Margin
6.74%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.